Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.
This is a randomized, double-blind, double-dummy, placebo controlled, inpatient, single-center, parallel group evaluation of the potential for oral donepezil to attenuate cocaine-induced craving. Non-treatment-seeking cocaine-experienced volunteers will receive baseline treatment with intravenous cocaine (30Mg). Forty-two subjects that tolerate baseline cocaine infusions will then receive two subsequent intravenous doses of cocaine during double-blind treatment with oral placebo or 5 mg daily of donepezil. Each dose of cocaine will be preceded or followed by administration of intravenous placebo (saline) in a random order.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oral Placebo First | Experimental | Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil |
|
| Donepezil First | Experimental | Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Donepezil, 5 mg daily | Drug | This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cocaine Safety in Subjects Receiving Donepezil | Patients evaluated for clinical and laboratory adverse events | Two weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Cocaine Subjective Effects | Cocaine Induced 'High' by VAS (visual analogue scale, between 3 and 30 minutes after intravenous dosing, in mm). VAS results ranged from 0 (minimum effect) to 100 (maximum effect). | 3 to 30 minutes |
| Cocaine Pharmacokinetics |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kenneth Grasing, MD | VA Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VA Medical Center | Kansas City | Missouri | 64128 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19836169 | Result | Grasing K, Mathur D, Newton TF, DeSouza C. Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug Alcohol Depend. 2010 Feb 1;107(1):69-75. doi: 10.1016/j.drugalcdep.2009.09.010. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo Treatment First | Participants initially treated with oral placebo, and later treated with oral donepezil |
| FG001 | Donepezil Treatment First | Participants initially treated with oral donepezil, and later treated with oral placebo |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
All participating subjects
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | All recruited subjects |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cocaine Safety in Subjects Receiving Donepezil | Patients evaluated for clinical and laboratory adverse events | All participants included | Posted | Number | Participants with an Adverse Event | Two weeks |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo Treatment Period | Inactive Comparator. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Gastrointestinal distress | Gastrointestinal disorders | Nausea | Systematic Assessment | One patient experienced a single episode of nausea and vomiting on his second day of treatment with donepezil that resolved spontaneously. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Kenneth Grasing | Substance Abuse Research Laboratory, Kansas City VA Medical Center | (816) 922-2756 | kenneth.grasing@va.gov |
Not provided
| ID | Term |
|---|---|
| D019970 | Cocaine-Related Disorders |
| D010146 | Pain |
| C537417 | Butyrylcholinesterase deficiency |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077265 | Donepezil |
| ID | Term |
|---|---|
| D007189 | Indans |
| D007192 | Indenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Oral Placebo | Other | Inactive Comparator with Similar Appearance to Active Medication |
|
|
Area-Under-the-Curve for Plasma Concentration |
| 0 to 8 hours |
| Years |
|
| Age, Categorical | Count of Participants | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Participants |
|
|
| Secondary | Cocaine Subjective Effects | Cocaine Induced 'High' by VAS (visual analogue scale, between 3 and 30 minutes after intravenous dosing, in mm). VAS results ranged from 0 (minimum effect) to 100 (maximum effect). | Posted | Mean | Standard Error | mm | 3 to 30 minutes |
|
|
|
| Secondary | Cocaine Pharmacokinetics | Area-Under-the-Curve for Plasma Concentration | Posted | Mean | Standard Error | ng-hr/ml | 0 to 8 hours |
|
|
|
| 0 |
| 12 |
| 0 |
| 12 |
| EG001 | Donepezil Treatment Period | Active Treatment | 0 | 12 | 2 | 12 |
|
| Chest discomfort | Gastrointestinal disorders | Discomfort | Systematic Assessment | An additional patient reported 5 minutes of mild chest discomfort that he attributed to eating too much during his third day of donepezil treatment, with no electrocardiogram changes observed. |
|
Not provided
Not provided
Not provided
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006844 |
| Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011083 | Polycyclic Compounds |